Research
Hormonal
Current glucose-lowering therapies, specifically metformin and bariatric surgery, alter intestinal IgA+ B cell populations and fecal secretory IgA levels, respectively.
If you are taking metformin or had bariatric surgery, part of their benefit may come from restoring gut IgA levels, which helps control inflammation and glucose.
GoodSupportsHIGH confidence
Current glucose-lowering therapies, including metformin, affect intestinal-related IgA+ B cell populations in mice, while bariatric surgery regimen alters the level of fecal secretory IgA in humans.
Why this rating
Directly links common therapies to the IgA mechanism.
Source
Gut-associated IgA+ immune cells regulate obesity-related insulin resistance
Helen Luck et al. · Nature Communications · 2019
DOI 10.1038/s41467-019-11370-y
mechanism_onlyCited 200×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →